|
Human Genome Sciences Inc - Company Profile Snapshot
| Company Profile: |
Human Genome Sciences Inc |
| Ticker: |
HGSI |
| Exchanges: |
NAS |
| 2008 Sales: |
48,422,000 |
| Major Industry: |
Miscellaneous |
| Sub Industry: |
Service Organizations |
| Country: |
UNITED STATES |
| Employees: |
880 |
Business Description
Human Genome Sciences Inc. The Group's principal activities are to develop, manufacture and market human protein and antibody drugs. The products of the Group are clinical development for chronic hepatitis C, LymphoStat-B(R) for systemic lupus erythematosus and ABthraxtm for inhalation anthrax. The Clinical development includes drugs to treat diseases like cancer, rheumatoid arthritis, lupus, hepatitis C, anthrax disease and HIV. It also has a portfolio of novel drugs in earlier stages of development, led by our TRAIL receptor antibodies in mid-stage development for cancer and including substantial financial rights to three novel drugs in the GlaxoSmithKline (GSK) clinical pipeline. It is developing Syncria as a treatment for type 2 diabetes mellitus. Syncria is generated from the genetic fusion of human albumin and GLP-1.
|
Not the Report you are looking for?
Click here for more browsing options.
|
The following information is available to subscribers or can be accessed by purchasing the Company Profile Report:
|
- Address (mailing), Phone Number, Web Address
- Earnings/Dividends
- Employees
- Exchanges Listed
- Financial Ratio Analysis |
- Recent Stock Performance
- Sales (recent year)
- Senior Officers
- Shareholder Information
- Stock Analysis Summary |
Layout and Content of a Typical Report
|
|
|
|
|
